Our multi-disciplinary team of legal professionals supports innovative pharmaceutical companies by providing practical, efficient and strategic legal advice that helps our clients navigate the competitive and rapidly changing environment in which they operate.


Our experience spans corporate governance, financing and M&A transactions, collaborations and licensing, intellectual property transactions, patent and product litigation and counseling, privacy and cybersecurity, tax, and IPO and securities law matters.



How we help our clients:


  • Venture Formation
  • Corporate transactions, including mergers and acquisitions
  • Commercial finance and restructurings
  • Corporate governance
  • Supply/distribution agreements
  • Franchising
  • International trade
  • Environmental and permitting
  • Patent prosecution
  • Licensing
  • Real Estate
  • Trademarks
  • Tax
  • Technology Transaction
  • Digital Asset Management
  • IP Protection
  • Data Breach Response
  • Cyber Liability Insurance
  • Digital Health Contracting
  • HIPAA Strategy
  • Data Governance

FIMI Opportunity Funds

Advised FIMI, a leading Israeli private equity firm on a number of acquisitions of Israeli pharmaceutical companies, its $220 million acquisition of RAFA Laboratories.


Israel Biotech Fund

Represented Israel Biotech Fund in its $14 million investment in Ayala Pharmaceuticals, a clinical-stage precision oncology company. We also represented the fund in its $30 million investment in Pharma Two B.



Advised aMoon in its $60 million investment in KAHR Medical, a developer of smart immune recruitment cancer drugs.


LogicBio Therapeutics

Represented LogicBio Therapeutics, a clinical-stage generic medicine company, in its $70 million NASDAQ IPO.



Represented Canabliss, a manufacturer of smoke-free cannabis products, in its acquisition by Together Pharma (TASE: TGTR).


Nacht Family Office

Advised Nacht Family Office on its $17 million investments in Mapi Pharma, a clinical-stage pharmaceutical company.


Teva Pharmaceuticals

Advised Teva Pharmaceuticals on a number of complex patentability and patent infringement matters involving the launch of new products.

matching results
  • 22 November 2021

    Naschitz Brandes Amir Advises Kamada on Acquisition of a Portfolio of Four FDA-Approved Commercial Products